Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. (Q38644464)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Priya S Kishnani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Patricia I Dickson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Laurie Muldowney

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jessica J Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Amy Rosenberg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Rekha Abichandani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jeffrey A Bluestone

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Barbara K Burton

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Maureen Dewey

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Alexandra Freitas

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Derek Gavin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Donna Griebel

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Melissa Hogan

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Stephen Holland

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Pranoot Tanpaiboon

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Laurence A Turka

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jeanine J Utz

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Yow-Ming Wang

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Chester B Whitley

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Anne R Pariser

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

10 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

66-83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

Measuring relative lysosomal volume for monitoring lysosomal storage diseases

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Clarifying lysosomal storage diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Lysosomal disorders: from storage to cellular damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Common and uncommon pathogenic cascades in lysosomal storage diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Prevalence of lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Newborn screening for lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Newborn screening for lysosomal storage disorders and other neuronopathic conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

The impact of antibodies in late-onset Pompe disease: a case series and literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Elimination of antibodies to recombinant enzyme in Pompe's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Genetic risk factors for inhibitors to factors VIII and IX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Considering Fabry, but Diagnosing MPS I: Difficulties in the Diagnostic Process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

The emerging phenotype of long-term survivors with infantile Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Immune modulation in Pompe disease treated with enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Immune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.11.001

10.1016/J.YMGME.2015.11.001

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597321%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference